-
Alarming rise in young-onset type 2 diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-06-06 The Lancet Diabetes & Endocrinology
-
Association between BMI and COVID-19 on hospital budgets Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-06-03 Maya Nitecki, Arnon Afek, Gilad Twig
-
Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-06-03 James Altunkaya MSc, Carmen Piernas PhD, Koen B Pouwels PhD, Susan A Jebb PhD, Philip Clarke PhD, Nerys M Astbury PhD, Jose Leal DPhil
Excess weight is a major risk factor for severe disease after infection with SARS-CoV-2. However, the effect of BMI on COVID-19 hospital resource use has not been fully quantified. This study aimed to identify the association between BMI and hospital resource use for COVID-19 admissions with the intention of informing future national hospital resource allocation. In this community-based cohort study
-
Lack of access to insulin: undermining the Rights of the Child Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-05-30 Olivia Heller, Olivier Duperrex, Philip D Jaffé, Jeffrey Goldhagen, Carol A Abidha, Ann Skelton, Mikiko Otani, Yvon Heller, Jean-Dominique Vassalli, David Beran
-
Diabetes distress: the psychological burden of living with diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-05-30 Lydia Poole, Ruth A Hackett
-
Causes, prevention, and management of diabetes-related foot ulcers Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-05-30 William Jeffcoate MRCP, Prof Edward J Boyko MD, Fran Game FRCP, Prue Cowled PhD, Prof Eric Senneville PhD, Prof Robert Fitridge FRACS
In this Review, we aim to complement the 2023 update of the guidelines of the International Working Group on the Diabetic Foot. We highlight the complexity of the pathological processes that underlie diabetes-related foot ulceration (DFU) and draw attention to the potential implications for clinical management and outcome. Variation observed in the incidence and outcome of DFUs in different communities
-
Advancing diabetes surveillance ecosystems: a case study of India Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-05-27 Jithin Sam Varghese PhD, Emily N Peterson PhD, Prof Mohammed K Ali MD, Prof Nikhil Tandon PhD
Professional society and expert guidelines recommend the achievement of glycaemic, blood pressure, and cholesterol targets to prevent the microvascular and macrovascular complications of diabetes. The WHO Diabetes Compact recommends that countries meet and monitor these targets for diabetes management. Surveillance—ie, continuous, systematic measurement, analysis, and interpretation of data—is a crucial
-
Prediction of progression to type 1 diabetes with dynamic biomarkers and risk scores Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-05-23 Mugdha V Joglekar PhD, Simranjeet Kaur PhD, Prof Flemming Pociot DMSc, Prof Anandwardhan A Hardikar PhD
Identifying biomarkers of functional β-cell loss is an important step in the risk stratification of type 1 diabetes. Genetic risk scores (GRS), generated by profiling an array of single nucleotide polymorphisms, are a widely used type 1 diabetes risk-prediction tool. Type 1 diabetes screening studies have relied on a combination of biochemical (autoantibody) and GRS screening methodologies for identifying
-
Measuring serum testosterone in women Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-05-22 Prof David J Handelsman MBBS PhD, Prof Susan R Davis MBBS PhD
-
The ongoing quest for worldwide iodine sufficiency Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-05-20 Ray Cavanaugh
-
SGLT2 inhibitors in clinical practice Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-05-17 Lars Rydén, Anna Norhammar
-
Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-05-17 Muhammad Shariq Usman MD, Prof Deepak L Bhatt MD, Ishaque Hameed MD, Prof Stefan D Anker MD, Alice Y Y Cheng MD, Prof Adrian F Hernandez MD, William Schuyler Jones MD, Muhammad Shahzeb Khan MD, Prof Mark C Petrie MD, Jacob A Udell MD, Prof Tim Friede PhD, Prof Javed Butler MD
Sodium–glucose co-transporter-2 (SGLT2) inhibitors have been studied in patients with heart failure, type 2 diabetes, chronic kidney disease, atherosclerotic cardiovascular disease, and acute myocardial infarction. Individual trials were powered to study composite outcomes in one disease state. We aimed to evaluate the treatment effect of SGLT2 inhibitors on specific clinical endpoints across multiple
-
Sleep: a neglected public health issue Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-05-10 The Lancet Diabetes & Endocrinology
-
Effect of population-wide screening for presymptomatic early-stage type 1 diabetes on paediatric clinical care Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-05-06 Ezio Bonifacio, Christiane Winkler, Peter Achenbach, Anette-Gabriele Ziegler
-
Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-05-06 Moath S Alsaqaaby MD, Sarah Cooney MD, Prof Carel W le Roux MD, Dimitri J Pournaras MD
Medications for obesity have been studied in various populations over the past three decades. We aimed to quantify the baseline demographic characteristics of BMI, sex, age, and race in randomised clinical trials (RCTs) across three decades to establish whether the population studied is representative of the global population affected by the disease. Clinical trials of 12 medications for obesity (ie
-
Melatonin: is it really a cardiovascular wonder pill for shift workers? Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-05-03 Pei Xue, Diana A Nôga, Christian Benedict
-
Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-05-03 Yanping Li PhD, Tianyi Huang DSc, Prof Susan Redline MD, Prof Walter C Willett MD, Prof JoAnn E Manson MD, Prof Eva S Schernhammer MD, Prof Frank B Hu MD
Use of melatonin supplements has been increasing substantially in both children and adults in the USA; however, their long-term cardiometabolic effects remain unclear. We aimed to assess the associations between regular use of melatonin supplements and the risk of developing type 2 diabetes or cardiovascular disease in adults. In this study, we included individuals from three US cohorts: the Nurses'
-
Setmelanotide: new promise for the treatment of hypothalamic obesity? Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-30 Manuel Tena-Sempere
-
Demarcating the benefits of hybrid closed loop therapy in pregnant women with type 1 diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-30 Helen R Murphy, Eleanor M Scott
-
Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-30 Katrien Benhalima MD, Kaat Beunen MSc, Nancy Van Wilder MD, Dominique Ballaux MD, Gerd Vanhaverbeke MD, Youri Taes MD, Xavier-Philippe Aers MD, Prof Frank Nobels MD, Joke Marlier MD, Dahae Lee MD, Joke Cuypers MD, Vanessa Preumont MD, Sarah E Siegelaar MD, Prof Rebecca C Painter MD, Annouschka Laenen PhD, Prof Pieter Gillard MD, Prof Chantal Mathieu MD
Advanced hybrid closed loop (AHCL) therapy can improve glycaemic control in pregnant women with type 1 diabetes. However, data are needed on the efficacy and safety of AHCL systems as these systems, such as the MiniMed 780G, are not currently approved for use in pregnant women. We aimed to investigate whether the MiniMed 780G can improve glycaemic control with less hypoglycaemia in pregnant women with
-
Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-30 Prof Christian L Roth MD, Cecilia Scimia MD, Ashley H Shoemaker MD, Prof Michael Gottschalk MD, Prof Jennifer Miller MD, Guojun Yuan PhD, Sonali Malhotra MD, M Jennifer Abuzzahab MD
Hypothalamic obesity resulting from hypothalamic damage might affect melanocortin signalling. We investigated the melanocortin-4 receptor agonist setmelanotide for treatment of hypothalamic obesity. This phase 2, open-label, multicentre trial was done in five centres in the USA. Eligible patients were aged between 6 and 40 years with obesity and history of hypothalamic injury or diagnosis of a non-malignant
-
Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-24 Dennis M Black, Austin R Thompson, Richard Eastell, Mary L Bouxsein
-
Anand Hardikar: a scientific nomad searching for the truth Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-23 Susan Rahimi, Marta Koch
-
Endpoints for clinical trials in type 1 diabetes drug development Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-23 Alfonso Galderisi, Brynn E Marks, Linda A DiMeglio, Carine de Beaufort
-
Food additive emulsifiers: a new risk factor for type 2 diabetes? Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-23 Mengxi Du, Frank B Hu
-
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-23 Mats Rasmussen, Morten Hach, Jørgen Iwersen, Gayathri Anil, Henrik Rosborg, Jens Larsen, Lise Camilla Hoffmann, Peter Kurtzhals
-
Environmental chemical obesogens, what can we do? Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-23 Tim Lobstein
-
Food additive emulsifiers and the risk of type 2 diabetes: analysis of data from the NutriNet-Santé prospective cohort study Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-23 Clara Salame PhD, Guillaume Javaux MSc, Laury Sellem PhD, Emilie Viennois PhD, Fabien Szabo de Edelenyi PhD, Cédric Agaësse RD, Alexandre De Sa RD, Inge Huybrechts PhD, Fabrice Pierre PhD, Prof Xavier Coumoul PhD, Prof Chantal Julia PhD, Emmanuelle Kesse-Guyot PhD, Benjamin Allès PhD, Léopold K Fezeu PhD, Prof Serge Hercberg PhD, Mélanie Deschasaux-Tanguy PhD, Prof Emmanuel Cosson MD, Sopio Tatulashvili
Experimental studies have suggested potential detrimental effects of emulsifiers on gut microbiota, inflammation, and metabolic perturbations. We aimed to investigate the associations between exposures to food additive emulsifiers and the risk of type 2 diabetes in a large prospective cohort of French adults. We analysed data from 104 139 adults enrolled in the French NutriNet-Santé prospective cohort
-
Rethinking the label anti-obesity medication Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-23 Stuart W Flint
-
Vitamin D supplements and future fracture risk among Mongolian schoolchildren Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-23 Ning Ma, Xia Cui, Wenquan Niu
-
Vitamin D supplements and future fracture risk among Mongolian schoolchildren – Author's reply Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-23 Adrian R Martineau, Polyna Khudyakov, Davaasambuu Ganmaa
-
Earth Day: time for transformational change Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-20 The Lancet Diabetes & Endocrinology
-
Improving support for university students with type 1 diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-17 Gijsbert Stoet, Emily Foster, Catherine Kerr, Lingqing Jiang, Megan-Ann Thornhill, Katarzyna Cyranka, Bartłomiej Matejko, Dominika Sarna-Palacz, Magdalena Płonka-Stępień, Tomasz Klupa
-
Endocrine health in survivors of adult-onset cancer Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-08 Cornelia S Link-Rachner MD, Andy Göbel PhD, Nikolai P Jaschke PhD, Tilman D Rachner MD
Long-term survivors of cancer (ie, the patient who is considered cured or for whom the disease is under long-term control and unlikely to recur) are at an increased risk of developing endocrine complications such as hypothalamic–pituitary dysfunctions, hypogonadisms, osteoporosis, or metabolic disorders, particularly when intensive tumour-directed therapies are applied. Symptom severity associated
-
Direct-to-consumer services: improving access to care for people with diabetes and obesity Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-05 Talha Burki
-
Glycaemic index as part of the diabetes prevention strategy Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-05 Gary Frost
-
Associations of the glycaemic index and the glycaemic load with risk of type 2 diabetes in 127 594 people from 20 countries (PURE): a prospective cohort study Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-04-05 Victoria Miller PhD, Prof David A Jenkins MD PhD, Mahshid Dehghan PhD, Kristie Srichaikul MD, Sumathy Rangarajan MSc, Andrew Mente PhD, Viswanathan Mohan DSc, Prof Sumathi Swaminathan PhD, Prof Rosnah Ismail DrPH, Maria Luz Diaz MD, Rekha M Ravindran PhD, Katarzyna Zatonska MD, Ahmad Bahonar MD, Prof Yuksel Altuntas MD, Rasha Khatib PhD, Prof Patricio Lopez-Jaramillo PhD, Afzalhussein Yusufali MD,
The association between the glycaemic index and the glycaemic load with type 2 diabetes incidence is controversial. We aimed to evaluate this association in an international cohort with diverse glycaemic index and glycaemic load diets. The PURE study is a prospective cohort study of 127 594 adults aged 35–70 years from 20 high-income, middle-income, and low-income countries. Diet was assessed at baseline
-
Type 1 diabetes: heterogeneity in heritability Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-29 Richard David Leslie
-
Familial aggregation and heritability of childhood-onset and adult-onset type 1 diabetes: a Swedish register-based cohort study Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-29 Yuxia Wei MSc, Shengxin Liu PhD, Tomas Andersson BSc, Prof Maria Feychting PhD, Ralf Kuja-Halkola PhD, Sofia Carlsson PhD
Type 1 diabetes in children is known to be highly heritable, but much less is known about the heritability of adult-onset type 1 diabetes. Thus, our objective was to compare the familial aggregation and heritability of type 1 diabetes in adults and children. This Swedish nationwide register-based cohort study included individuals born from Jan 1, 1982, to Dec 31, 2010, identified through the Medical
-
How clinically relevant is statin-induced diabetes? Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-27 Hertzel C Gerstein, Marie Pigeyre
-
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-27 Cholesterol Treatment Trialists’ (CTT) Collaboration, Christina Reith, David Preiss, Lisa Blackwell, Jonathan Emberson, Enti Spata, Kelly Davies, Heather Halls, Charlie Harper, Lisa Holland, Kate Wilson, Alistair J Roddick, Christopher P Cannon, Robert Clarke, Helen M Colhoun, Paul N Durrington, Shinya Goto, Graham A Hitman, G Kees Hovingh, J Wouter Jukema, Wolfgang Koenig, Ian Marschner, Borislava
-
Disparities in fragility fracture and osteoporosis care in Africa Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-22 Kate A Ward, Tafadzwa Madanhire, Kebba Marenah, Lisa K Micklesfield, Celia L Gregson
-
Bridging the worlds of research and policy making Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-19 Jonathan Valabhji
-
Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation – Authors' reply Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-19 Kausik K Ray, LeAnne Bloedon, Na Li, Steven E Nissen, on behalf of the co-authors
-
Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-19 Dion Groothof, Stephan J L Bakker
-
Tight versus liberal blood-glucose control in the intensive care unit: special considerations for patients with diabetes Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-19 Christian von Loeffelholz MD, Prof Andreas L Birkenfeld MD
Stress hyperglycaemia, hypoglycaemia, and diabetes are common in critically ill patients and related to clinical endpoints. To avoid complications related to hypoglycaemia and hyperglycaemia, it is recommended to start insulin therapy for the majority of critically ill patients with persistent blood glucose concentrations higher than 10·0 mmol/L (>180 mg/dL), targeting a range of 7·8–10·0 mmol/L (140–180
-
Undiagnosed type 2 diabetes: an invisible risk factor Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-06 The Lancet Diabetes & Endocrinology
-
-
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-04 Paulina Salminen
-
Optimising zoledronate treatment holiday duration without loss of fracture prevention Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-04 Matthew T Drake
-
Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass at 5 years (YOMEGA): a prospective, open-label, non-inferiority, randomised extension study Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-04 Prof Maud Robert MD, Tigran Poghosyan MD, Prof Delphine Maucort-Boulch MD, Dr Alexandre Filippello MD, Prof Robert Caiazzo MD, Adrien Sterkers MD, Lita Khamphommala MD, Prof Fabian Reche MD, Vincent Malherbe MD, Adriana Torcivia MD, Toufic Saber MD, Dominique Delaunay PhD, Carole Langlois-Jacques MSc, Augustin Suffisseau MD, Sylvie Bin MD, Prof Emmanuel Disse MD, Prof François Pattou MD
The multicentre randomised trial YOMEGA () comparing the one anastomosis gastric bypass (OAGB) with the Roux-en-Y gastric bypass (RYGB) confirmed the non-inferiority of OAGB on weight loss outcomes at 24 months. We aimed to report weight loss, metabolic, and safety outcomes at 5 years. YOMEGA is a prospective, open-label, non-inferiority, randomised trial conducted at nine centres in France. Inclusion
-
Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-04 Prof Ian R Reid MD, Anne M Horne MBChB, Borislav Mihov BPhty, Usha Bava MHSc, Angela Stewart RN, Gregory D Gamble MSc
We previously identified that zoledronate administered at 18-month intervals reduced fragility fractures by a third in a 6-year trial of women older than 65 years with osteopenia. This extension aims to identify the persistence of these effects. Of the 2000 ambulant, community dwelling, postmenopausal women older than 65 years recruited in Auckland, New Zealand, with T-scores at the total hip or femoral
-
Reversibility of congenital hypogonadotropic hypogonadism: lessons from a rare disease Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-01 Bradley D Anawalt
-
Classes and predictors of reversal in male patients with congenital hypogonadotropic hypogonadism: a cross-sectional study of six international referral centres Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-03-01 Andrew A Dwyer PhD, Isabella R McDonald DNP, Biagio Cangiano MD, Luca Giovanelli MD, Luigi Maione MD, Leticia F G Silveira MD, Prof Taneli Raivio MD PhD, Prof Ana Claudia Latronico MD PhD, Prof Jacques Young MD PhD, Richard Quinton MD, Marco Bonomi MD, Prof Luca Persani MD PhD, Prof Stephanie B Seminara MD, Prof Christopher S Lee PhD
Although some male patients with congenital hypogonadotropic hypogonadism (CHH) undergo spontaneous reversal following treatment, predictors of reversal remain elusive. We aimed to assemble the largest cohort of male patients with CHH reversal to date and identify distinct classes of reversal. This multicentre cross-sectional study was conducted in six international CHH referral centres in Brazil,
-
Type 2 diabetes remission: weight maintenance in the spotlight Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-02-28 Shahrad Taheri
-
CONCEPTT to care: the science of implementation in diabetes care Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-02-26 Eleanor M Scott, Helen R Murphy, Karen Kennedy, Partha Kar
-
5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-02-26 Prof Michael EJ Lean MD, Wilma S Leslie PhD, Alison C Barnes PGDip, Naomi Brosnahan PhD, George Thom PhD, Louise McCombie BSc, Tara Kelly BSc, Keaton Irvine MSci, Carl Peters MB, Sviatlana Zhyzhneuskaya MD, Prof Kieren G Hollingsworth PhD, Prof Ashley J Adamson PhD, Prof Falko F Sniehotta PhD, Prof John C Mathers PhD, Yvonne McIlvenna MSc, Prof Paul Welsh PhD, Prof Alex McConnachie PhD, Alasdair McIntosh
In DiRECT, a randomised controlled effectiveness trial, weight management intervention after 2 years resulted in mean weight loss of 7·6 kg, with 36% of participants in remission of type 2 diabetes. Of 36 in the intervention group who maintained over 10 kg weight loss at 2 years, 29 (81%) were in remission. Continued low-intensity dietary support was then offered up to 5 years from baseline to intervention
-
Living between two worlds: lessons for community involvement Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-02-20 Ashley H Ng, Matthew Quigley, Tim Benson, Lauren Cusack, Rachel Hicks, Ben Nash, Meaghan Read, Renza Scibilia, Cheryl Steele, Leon Tribe, Elizabeth Holmes-Truscott
-
Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2023 Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-02-20
-
Milestone achievement for global access to blood glucose meters and test strips Lancet Diabetes Endocrinol. (IF 44.0) Pub Date : 2024-02-20 Emma Klatman, Beatrice Vetter, Cathy Haldane, Graham Ogle